스타틴 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(-2031년) - 약물 종류별, 치료법별, 최종사용자별, 지역별

Statins Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

US $ 4,995 ￦ 6,853,000

Unprintable PDF & Excel (Single User License)

PDF 및 Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 텍스트의 Copy&Paste도 불가능합니다.

US $ 8,495 ￦ 11,655,000

Unprintable PDF & Excel (Multi User License upto 5 users)

PDF 및 Excel 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 텍스트는 Copy & Paste 가능하지만, 인쇄는 불가능합니다.

US $ 10,600 ￦ 14,544,000

Printable PDF & Excel (Enterprise License above 5 users)

PDF 및 Excel 보고서를 동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용자수는 5명 이상이며 제한은 없습니다. Copy & Paste 및 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계 스타틴 시장 규모는 꾸준한 성장 궤도에 있으며, 2024년에는 154억 달러, 2031년에는 210억 달러에 달할 것으로 예상됩니다.

스타틴에 대한 세계 수요는 전 세계적으로 고콜레스테롤 및 비만 유병률의 증가로 인해 큰 영향을 받고 있습니다. 생활습관의 변화와 앉아서 생활하는 습관이 고콜레스테롤 수치의 증가로 이어지면서 스타틴은 콜레스테롤 관리에 필수적인 솔루션이 되고 있습니다.

스타틴은 생활습관 개선만으로는 조절하기 어려운 고콜레스테롤 수치를 조절하는 데 중요한 역할을 하고 있습니다. 또한, 인식 개선 노력과 선진화된 의료 시설도 스타틴 수요 확대에 기여하고 있습니다.

또한, 에제티미브와 같은 다른 콜레스테롤 저하제와 함께 스타틴을 포함한 병용요법의 채택이 세계 시장을 더욱 견인할 것으로 예상됩니다. 스타틴과 에제티미브의 병용요법은 거의 정상적인 지질 프로필을 달성하고 심혈관 질환의 위험을 줄일 수 있을 것으로 기대됩니다.

스타틴 시장은 성장세를 보이고 있지만, 높은 제조 비용과 제조 공정의 복잡성으로 인해 여전히 많은 어려움이 있습니다. 또한 엄격한 분석적 특성화 및 규제 당국의 승인 절차를 통해 바이오시밀러를 확립하는 것은 여전히 시간과 비용이 많이 드는 과정입니다.

그러나 연구개발에 대한 투자 증가, 의료시설 개선에 대한 높은 관심, 민관 간 전략적 협력 관계는 스타틴 제조업체에 성장 기회를 제공할 것으로 예상됩니다.

이 보고서는 세계 스타틴 시장에 대해 조사했으며, 시장 개요와 함께 약물 종류별, 치료법별, 최종사용자별, 지역별 동향, 시장 진입 기업의 경쟁 동향 등을 제공합니다.

목차

제1장 주요 요약

제2장 시장 개요

• 시장 정의와 세분화
• 시장 역학
• 밸류체인 분석
• Porter's Five Forces 분석
• COVID-19의 영향 분석
• 우크라이나와 러시아 분쟁의 영향
• 경제 개요
• PESTLE 분석

제3장 생산량과 무역 통계, 2018-2023년

제4장 가격 분석, 2018-2023년

제5장 세계의 스타틴 시장 전망, 2018-2031년

• 세계의 스타틴 시장 전망, 약제 클래스별, 금액(10억 달러), 수량, 2018-2031년
• 세계의 스타틴 시장 전망, 치료법별, 금액(10억 달러), 수량, 2018-2031년
• 세계의 스타틴 시장 전망, 최종사용자별, 금액(10억 달러), 수량, 2018-2031년
• 세계의 스타틴 시장 전망, 지역별, 금액(10억 달러), 수량, 2018-2031년

제6장 북미의 스타틴 시장 전망, 2018-2031년

제7장 유럽의 스타틴 시장 전망, 2018-2031년

제8장 아시아태평양의 스타틴 시장 전망, 2018-2031년

제9장 라틴아메리카의 스타틴 시장 전망, 2018-2031년

제10장 중동 및 아프리카의 스타틴 시장 전망, 2018-2031년

제11장 경쟁 상황

• 최종사용자별과 치료법별 히트맵
• 기업의 시장 점유율 분석, 2023년
• 경쟁력 대시보드
• 기업 개요
  • Pfizer Inc.
  • AstraZeneca plc
  • Novartis International AG
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Biocon
  • Aurobindo Pharma Ltd
  • Concord Biotech

제12장 부록

ksm

영문 목차

영문목차

North America Dominates the Market, with the United States Leading in Statin Usage

Rising Obesity and Cardiovascular Disease Cases Boost Demand for Statins Worldwide

The global statins market is on a steady growth trajectory and is expected to reach a valuation of US$ 21 billion by 2031. In 2024, the market was valued at US$ 15.4 billion.

Market Dynamics

The global demand for statins is being significantly influenced by the increasing incidence of high cholesterol and obesity cases worldwide. Lifestyle changes and sedentary habits have led to a rise in high cholesterol levels, making statins an essential solution for cholesterol management.

Statins play a crucial role in addressing high cholesterol levels that are difficult to control solely through lifestyle modifications. Additionally, awareness initiatives and advanced healthcare facilities are contributing to the growing demand for statins.

Moreover, the adoption of combination therapies that include statins alongside other cholesterol-lowering medications, such as ezetimibe, is expected to further drive the global market. Statin-ezetimibe combination therapy has shown promise in achieving near-normal lipid profiles, reducing the risk of cardiovascular diseases.

Challenges and Opportunities

While the statins market is poised for growth, challenges persist, primarily related to high manufacturing costs and the complexity of the production process. Additionally, establishing biosimilarity through rigorous analytical characterization and regulatory approval procedures remains a time-consuming and costly process.

However, increasing investments in research and development, a strong focus on improving healthcare facilities, and strategic collaborations between public and private entities are expected to provide growth opportunities for statin manufacturers.

Regional Analysis

North America is at the forefront of the global statins market and is poised to maintain its dominance throughout the forecast period. The region has a significant population suffering from cardiovascular diseases, diabetes, and obesity, driving the demand for effective cholesterol management solutions.

The United States is expected to lead the statins market in North America, with organizations like the American Heart Association and the American College of Cardiology issuing guidelines that recommend statin usage for individuals at risk of heart attacks.

Product Analysis

Statins are a class of drugs used to lower blood cholesterol levels, particularly low-density lipoprotein (LDL) cholesterol. The market for statins has witnessed steady growth, driven by increased healthcare awareness and the rising prevalence of cholesterol-related conditions.

While maintaining a healthy lifestyle can help manage cholesterol, sedentary habits have contributed to a growing need for statin therapy, particularly among the elderly population.

Key Players

Prominent players in the global statins market include: Pfizer Inc., AstraZeneca plc, Novartis International AG, GlaxoSmithKline plc, Merck & Co., Inc., Biocon, Aurobindo Pharma Ltd, and Concord Biotech.

Statins Industry Research Segmentation

By Drug Class:

• Astrovastatins
• Fluvastatins
• Lovastatins
• Pravastatins
• Simvastatins
• Others

By Therapeutic Treatment:

• Cardiovascular Disorders
• Obesity
• Inflammatory Disorders
• Others

By End User:

• Hospitals
• Clinics

By Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa

Table of Contents

1. Executive Summary

• 1.1. Global Statins Market Snapshot
• 1.2. Future Projections
• 1.3. Key Market Trends
• 1.4. Regional Snapshot, by Value and Volume, 2023
• 1.5. Analyst Recommendations

2. Market Overview

• 2.1. Market Definitions and Segmentations
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Market Opportunities
• 2.3. Value Chain Analysis
• 2.4. Porter's Five Forces Analysis
• 2.5. COVID-19 Impact Analysis
  • 2.5.1. Supply
  • 2.5.2. Demand
• 2.6. Impact of Ukraine-Russia Conflict
• 2.7. Economic Overview
  • 2.7.1. World Economic Projections
• 2.8. PESTLE Analysis

3. Production Output and Trade Statistics, 2018 - 2023

• 3.1. Global Statins Production Output, by Region, Value (US$ Bn) and Volume, 2018 - 2023
  • 3.1.1. North America
  • 3.1.2. Europe
  • 3.1.3. Asia Pacific
  • 3.1.4. Latin America
  • 3.1.5. Middle East and Africa

4. Price Analysis, 2018 - 2023

• 4.1. Global Average Price Analysis by Drug Class, 2018 - 2023
• 4.2. Prominent Factor Affecting Statins Prices
• 4.3. Global Average Price Analysis by Region

5. Global Statins Market Outlook, 2018 - 2031

• 5.1. Global Statins Market Outlook, by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
  • 5.1.1. Key Highlights
    • 5.1.1.1. Astrovastatins
    • 5.1.1.2. Fluvastatins
    • 5.1.1.3. Lovastatins
    • 5.1.1.4. Pravastatins
    • 5.1.1.5. Simvastatins
    • 5.1.1.6. Others
• 5.2. Global Statins Market Outlook, by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
  • 5.2.1. Key Highlights
    • 5.2.1.1. Cardiovascular Disorders
    • 5.2.1.2. Obesity
    • 5.2.1.3. Inflammatory Disorders
    • 5.2.1.4. Others
• 5.3. Global Statins Market Outlook, by End User, Value (US$ Bn) and Volume, 2018 - 2031
  • 5.3.1. Key Highlights
    • 5.3.1.1. Hospitals
    • 5.3.1.2. Clinics
• 5.4. Global Statins Market Outlook, by Region, Value (US$ Bn) and Volume, 2018 - 2031
  • 5.4.1. Key Highlights
    • 5.4.1.1. North America
    • 5.4.1.2. Europe
    • 5.4.1.3. Asia Pacific
    • 5.4.1.4. Latin America
    • 5.4.1.5. Middle East & Africa

6. North America Statins Market Outlook, 2018 - 2031

• 6.1. North America Statins Market Outlook, by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
  • 6.1.1. Key Highlights
    • 6.1.1.1. Astrovastatins
    • 6.1.1.2. Fluvastatins
    • 6.1.1.3. Lovastatins
    • 6.1.1.4. Pravastatins
    • 6.1.1.5. Simvastatins
    • 6.1.1.6. Others
• 6.2. North America Statins Market Outlook, by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
  • 6.2.1. Key Highlights
    • 6.2.1.1. Cardiovascular Disorders
    • 6.2.1.2. Obesity
    • 6.2.1.3. Inflammatory Disorders
    • 6.2.1.4. Others
• 6.3. North America Statins Market Outlook, by End User, Value (US$ Bn) and Volume, 2018 - 2031
  • 6.3.1. Key Highlights
    • 6.3.1.1. Hospitals
    • 6.3.1.2. Clinics
  • 6.3.2. BPS Analysis/Market Attractiveness Analysis
• 6.4. North America Statins Market Outlook, by Country, Value (US$ Bn) and Volume, 2018 - 2031
  • 6.4.1. Key Highlights
    • 6.4.1.1. U.S. Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
    • 6.4.1.2. U.S. Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
    • 6.4.1.3. U.S. Statins Market by End User, Value (US$ Bn) and Volume, 2018 - 2031
    • 6.4.1.4. Canada Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
    • 6.4.1.5. Canada Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
    • 6.4.1.6. Canada Statins Market by End User, Value (US$ Bn) and Volume, 2018 - 2031
  • 6.4.2. BPS Analysis/Market Attractiveness Analysis

7. Europe Statins Market Outlook, 2018 - 2031

• 7.1. Europe Statins Market Outlook, by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
  • 7.1.1. Key Highlights
    • 7.1.1.1. Astrovastatins
    • 7.1.1.2. Fluvastatins
    • 7.1.1.3. Lovastatins
    • 7.1.1.4. Pravastatins
    • 7.1.1.5. Simvastatins
    • 7.1.1.6. Others
• 7.2. Europe Statins Market Outlook, by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
  • 7.2.1. Key Highlights
    • 7.2.1.1. Cardiovascular Disorders
    • 7.2.1.2. Obesity
    • 7.2.1.3. Inflammatory Disorders
    • 7.2.1.4. Others
• 7.3. Europe Statins Market Outlook, by End User, Value (US$ Bn) and Volume, 2018 - 2031
  • 7.3.1. Key Highlights
    • 7.3.1.1. Hospitals
    • 7.3.1.2. Clinics
  • 7.3.2. Attractiveness Analysis
• 7.4. Europe Statins Market Outlook, by Country, Value (US$ Bn) and Volume, 2018 - 2031
  • 7.4.1. Key Highlights
    • 7.4.1.1. Germany Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
    • 7.4.1.2. Germany Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
    • 7.4.1.3. Germany Statins Market by End User, Value (US$ Bn) and Volume, 2018 - 2031
    • 7.4.1.4. U.K. Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
    • 7.4.1.5. U.K. Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
    • 7.4.1.6. U.K. Statins Market by End User, Value (US$ Bn) and Volume, 2018 - 2031
    • 7.4.1.7. France Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
    • 7.4.1.8. France Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
    • 7.4.1.9. France Statins Market by End User, Value (US$ Bn) and Volume, 2018 - 2031
    • 7.4.1.10. Italy Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
    • 7.4.1.11. Italy Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
    • 7.4.1.12. Italy Statins Market by End User, Value (US$ Bn) and Volume, 2018 - 2031
    • 7.4.1.13. Turkey Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
    • 7.4.1.14. Turkey Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
    • 7.4.1.15. Turkey Statins Market by End User, Value (US$ Bn) and Volume, 2018 - 2031
    • 7.4.1.16. Russia Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
    • 7.4.1.17. Russia Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
    • 7.4.1.18. Russia Statins Market by End User, Value (US$ Bn) and Volume, 2018 - 2031
    • 7.4.1.19. Rest of Europe Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
    • 7.4.1.20. Rest of Europe Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
    • 7.4.1.21. Rest of Europe Statins Market by End User, Value (US$ Bn) and Volume, 2018 - 2031
  • 7.4.2. BPS Analysis/Market Attractiveness Analysis

8. Asia Pacific Statins Market Outlook, 2018 - 2031

• 8.1. Asia Pacific Statins Market Outlook, by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
  • 8.1.1. Key Highlights
    • 8.1.1.1. Astrovastatins
    • 8.1.1.2. Fluvastatins
    • 8.1.1.3. Lovastatins
    • 8.1.1.4. Pravastatins
    • 8.1.1.5. Simvastatins
    • 8.1.1.6. Others
• 8.2. Asia Pacific Statins Market Outlook, by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
  • 8.2.1. Key Highlights
    • 8.2.1.1. Cardiovascular Disorders
    • 8.2.1.2. Obesity
    • 8.2.1.3. Inflammatory Disorders
    • 8.2.1.4. Others
• 8.3. Asia Pacific Statins Market Outlook, by End User, Value (US$ Bn) and Volume, 2018 - 2031
  • 8.3.1. Key Highlights
    • 8.3.1.1. Hospitals
    • 8.3.1.2. Clinics
  • 8.3.2. BPS Analysis/Market Attractiveness Analysis
• 8.4. Asia Pacific Statins Market Outlook, by Country, Value (US$ Bn) and Volume, 2018 - 2031
  • 8.4.1. Key Highlights
    • 8.4.1.1. China Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
    • 8.4.1.2. China Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
    • 8.4.1.3. China Statins Market by End User, Value (US$ Bn) and Volume, 2018 - 2031
    • 8.4.1.4. Japan Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
    • 8.4.1.5. Japan Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
    • 8.4.1.6. Japan Statins Market by End User, Value (US$ Bn) and Volume, 2018 - 2031
    • 8.4.1.7. South Korea Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
    • 8.4.1.8. South Korea Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
    • 8.4.1.9. South Korea Statins Market by End User, Value (US$ Bn) and Volume, 2018 - 2031
    • 8.4.1.10. India Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
    • 8.4.1.11. India Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
    • 8.4.1.12. India Statins Market by End User, Value (US$ Bn) and Volume, 2018 - 2031
    • 8.4.1.13. Southeast Asia Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
    • 8.4.1.14. Southeast Asia Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
    • 8.4.1.15. Southeast Asia Statins Market by End User, Value (US$ Bn) and Volume, 2018 - 2031
    • 8.4.1.16. Rest of Asia Pacific Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
    • 8.4.1.17. Rest of Asia Pacific Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
    • 8.4.1.18. Rest of Asia Pacific Statins Market by End User, Value (US$ Bn) and Volume, 2018 - 2031
  • 8.4.2. BPS Analysis/Market Attractiveness Analysis

9. Latin America Statins Market Outlook, 2018 - 2031

• 9.1. Latin America Statins Market Outlook, by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
  • 9.1.1. Key Highlights
    • 9.1.1.1. Astrovastatins
    • 9.1.1.2. Fluvastatins
    • 9.1.1.3. Lovastatins
    • 9.1.1.4. Pravastatins
    • 9.1.1.5. Simvastatins
    • 9.1.1.6. Others
• 9.2. Latin America Statins Market Outlook, by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
  • 9.2.1. Key Highlights
    • 9.2.1.1. Cardiovascular Disorders
    • 9.2.1.2. Obesity
    • 9.2.1.3. Inflammatory Disorders
    • 9.2.1.4. Others
• 9.3. Latin America Statins Market Outlook, by End User, Value (US$ Bn) and Volume, 2018 - 2031
  • 9.3.1. Key Highlights
    • 9.3.1.1. Hospitals
    • 9.3.1.2. Clinics
  • 9.3.2. BPS Analysis/Market Attractiveness Analysis
• 9.4. Latin America Statins Market Outlook, by Country, Value (US$ Bn) and Volume, 2018 - 2031
  • 9.4.1. Key Highlights
    • 9.4.1.1. Brazil Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
    • 9.4.1.2. Brazil Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
    • 9.4.1.3. Brazil Statins Market by End User, Value (US$ Bn) and Volume, 2018 - 2031
    • 9.4.1.4. Mexico Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
    • 9.4.1.5. Mexico Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
    • 9.4.1.6. Mexico Statins Market by End User, Value (US$ Bn) and Volume, 2018 - 2031
    • 9.4.1.7. Argentina Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
    • 9.4.1.8. Argentina Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
    • 9.4.1.9. Argentina Statins Market by End User, Value (US$ Bn) and Volume, 2018 - 2031
    • 9.4.1.10. Rest of Latin America Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
    • 9.4.1.11. Rest of Latin America Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
    • 9.4.1.12. Rest of Latin America Statins Market by End User, Value (US$ Bn) and Volume, 2018 - 2031
  • 9.4.2. BPS Analysis/Market Attractiveness Analysis

10. Middle East & Africa Statins Market Outlook, 2018 - 2031

• 10.1. Middle East & Africa Statins Market Outlook, by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
  • 10.1.1. Key Highlights
    • 10.1.1.1. Astrovastatins
    • 10.1.1.2. Fluvastatins
    • 10.1.1.3. Lovastatins
    • 10.1.1.4. Pravastatins
    • 10.1.1.5. Simvastatins
    • 10.1.1.6. Others
• 10.2. Middle East & Africa Statins Market Outlook, by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
  • 10.2.1. Key Highlights
    • 10.2.1.1. Cardiovascular Disorders
    • 10.2.1.2. Obesity
    • 10.2.1.3. Inflammatory Disorders
    • 10.2.1.4. Others
• 10.3. Middle East & Africa Statins Market Outlook, by End User, Value (US$ Bn) and Volume, 2018 - 2031
  • 10.3.1. Key Highlights
    • 10.3.1.1. Hospitals
    • 10.3.1.2. Clinics
  • 10.3.2. BPS Analysis/Market Attractiveness Analysis
• 10.4. Middle East & Africa Statins Market Outlook, by Country, Value (US$ Bn) and Volume, 2018 - 2031
  • 10.4.1. Key Highlights
    • 10.4.1.1. GCC Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
    • 10.4.1.2. GCC Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
    • 10.4.1.3. GCC Statins Market by End User, Value (US$ Bn) and Volume, 2018 - 2031
    • 10.4.1.4. South Africa Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
    • 10.4.1.5. South Africa Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
    • 10.4.1.6. South Africa Statins Market by End User, Value (US$ Bn) and Volume, 2018 - 2031
    • 10.4.1.7. Egypt Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
    • 10.4.1.8. Egypt Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
    • 10.4.1.9. Egypt Statins Market by End User, Value (US$ Bn) and Volume, 2018 - 2031
    • 10.4.1.10. Nigeria Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
    • 10.4.1.11. Nigeria Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
    • 10.4.1.12. Nigeria Statins Market by End User, Value (US$ Bn) and Volume, 2018 - 2031
    • 10.4.1.13. Rest of Middle East & Africa Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
    • 10.4.1.14. Rest of Middle East & Africa Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
    • 10.4.1.15. Rest of Middle East & Africa Statins Market by End User, Value (US$ Bn) and Volume, 2018 - 2031
  • 10.4.2. BPS Analysis/Market Attractiveness Analysis

11. Competitive Landscape

• 11.1. By End User vs by Therapeutic Treatment Heatmap
• 11.2. Company Market Share Analysis, 2023
• 11.3. Competitive Dashboard
• 11.4. Company Profiles
  • 11.4.1. Pfizer Inc.
    • 11.4.1.1. Company Overview
    • 11.4.1.2. Product Portfolio
    • 11.4.1.3. Financial Overview
    • 11.4.1.4. Business Strategies and Development
  • 11.4.2. AstraZeneca plc
    • 11.4.2.1. Company Overview
    • 11.4.2.2. Product Portfolio
    • 11.4.2.3. Financial Overview
    • 11.4.2.4. Business Strategies and Development
  • 11.4.3. Novartis International AG
    • 11.4.3.1. Company Overview
    • 11.4.3.2. Product Portfolio
    • 11.4.3.3. Financial Overview
    • 11.4.3.4. Business Strategies and Development
  • 11.4.4. GlaxoSmithKline plc
    • 11.4.4.1. Company Overview
    • 11.4.4.2. Product Portfolio
    • 11.4.4.3. Financial Overview
    • 11.4.4.4. Business Strategies and Development
  • 11.4.5. Merck & Co., Inc.
    • 11.4.5.1. Company Overview
    • 11.4.5.2. Product Portfolio
    • 11.4.5.3. Financial Overview
    • 11.4.5.4. Business Strategies and Development
  • 11.4.6. Biocon
    • 11.4.6.1. Company Overview
    • 11.4.6.2. Product Portfolio
    • 11.4.6.3. Financial Overview
    • 11.4.6.4. Business Strategies and Development
  • 11.4.7. Aurobindo Pharma Ltd
    • 11.4.7.1. Company Overview
    • 11.4.7.2. Product Portfolio
    • 11.4.7.3. Financial Overview
    • 11.4.7.4. Business Strategies and Development
  • 11.4.8. Concord Biotech
    • 11.4.8.1. Company Overview
    • 11.4.8.2. Product Portfolio
    • 11.4.8.3. Financial Overview
    • 11.4.8.4. Business Strategies and Development

12. Appendix

• 12.1. Research Methodology
• 12.2. Report Assumptions
• 12.3. Acronyms and Abbreviations

관련자료